# A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

> **NCT05909904** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 160 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** BGB-A425
- **DRUG:** LBL-007

## Key facts

- **NCT ID:** NCT05909904
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-21
- **Primary completion:** 2025-06-17
- **Final completion:** 2026-05-28
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909904, "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05909904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*